Showing 7641-7650 of 8649 results for "".
- Study: Hospitals At or Near Full COVID-19 ICU Capacity Increase by 90% Over Past Few Monthshttps://modernod.com/news/study-hospitals-at-or-near-full-covid-19-icu-capacity-increase-by-90-over-past-few-months/2478722/A new study found a 90% increase in hospitals reaching intensive care unit (ICU) capacity from July through December, with rural hospitals facing the biggest capacity issues, according to a FierceHealthcare
- FDA Knocks Proposals to Tinker With COVID-19 Vaccine Regimenshttps://modernod.com/news/fda-knocks-proposals-to-tinker-with-covid-19-vaccine-regimens/2478714/The FDA indicated that it has no plans to make any dosing or scheduling changes to the two COVID-19 vaccines currently authorized in the US, saying doing so at this time would be “premature and not rooted solidly in the available evidence.” The statement came in response to various pr
- Moderna Boosts COVID-19 Vaccine Output for 2021 to at Least 600 Million Doseshttps://modernod.com/news/moderna-boosts-covid-19-vaccine-output-for-2021-to-at-least-600-million-doses/2478715/Moderna said it expects to produce a minimum of 600 million doses of its COVID-19 vaccine mRNA-1273 globally this year, up from an earlier estimate of 500 million, and that it is still working to build up to potentially 1 billion doses for 2021. The company also plans to deliver about 100 million
- WHO Validates Pfizer, BioNTech’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/who-validates-pfizer-biontechs-covid-19-vaccine-for-emergency-use/2478709/The World Health Organization (WHO) said Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 became the first vaccine to receive WHO validation for emergency use since the pandemic began. According to the WHO, BNT162b2 has met the agency’s “must-have” criteria for safety and e
- Surgery Equals Drug Treatment for Bleeding in Diabetic Retinopathyhttps://modernod.com/news/surgery-equals-drug-treatment-for-bleeding-in-diabetic-retinopathy/2478705/In the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, intraocular injection with anti–vascular endothelial growth factor (VEGF) shows similar efficacy to that of vitrectomy with photocoagulation; however, patients commonly require both treatments, new research shows, ac
- Nicox’s Partner Ocumension Therapeutics Initiates Zerviate Phase 3 Clinical Trial in Chinahttps://modernod.com/news/nicoxs-partner-ocumension-therapeutics-initiates-zerviate-phase-3-clinical-trial-in-china/2478704/Nicox SA announced that its partner, Ocumension Therapeutics, has initiated a phase 3 clinical trial in China with Zerviate, the first and only topical ocular formulation of the anti
- Ocugen and Bharat Biotech to Co-Develop COVID-19 Vaccine for the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-to-co-develop-covaxin-covid-19-vaccine-for-the-us-market/2478692/Ophthalmic biopharma company Ocugen has signed a letter of intent to co-develop Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, an advanced stage whole-viron inactivated vaccine candidate, for the United States market. Covaxin has been evaluated in approximately 1,000 subjects in pha
- From COVID-19 to Retail Health: Fierce Healthcare’s Biggest Stories of 2020https://modernod.com/news/from-covid-19-to-retail-health-fierce-healthcares-biggest-stories-of-2020/2478689/The year 2020 was dominated by the fallout from a generational global pandemic. So perhaps it’s no surprise that COVID-19 headlines also governed much of
- Federal Guidance Enables Employers to Mandate Workers Get COVID-19 Vaccinehttps://modernod.com/news/federal-guidance-enables-employers-to-mandate-workers-get-covid-19-vaccine/2478682/New guidance from the Equal Employment Opportunity Commission allows employers to require workers to get COVID-19 vaccinations, which has major implications for providers, according to a FierceHealthcare
- CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidatehttps://modernod.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/CureVac NV announced that the first participant in a clinical phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a